logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 10 of 10 Items
Showing 1 - 10 of 10 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Conference Material
|
Poster

Clinical profile and response to treatment of patients with peripheral tubercular lymphadenitis

Maich G, Kumar N, Anuradha S, Pradhan GS, Verma N
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024
Journal Article
|
Research

AmBisome monotherapy and combination AmBisome - miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: a randomised open label, parallel arm, phase 3 trial

Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
Journal Article
|
Research

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

Burza S, Mahajan R, Singh A, van Griensven J, Pandey K,  et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 obs...
Conference Material
|
Abstract

Prevalence of asymptomatic Leishmania infection in HIV-positive people and progression to symptomatic visceral leishmaniasis in Bihar, India.

Mahajan R, Owen SI, Kumar S, Kazmi S, Das P,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
People co-infected with visceral leishmaniasis and HIV (VL-HIV) typically present with advanced HIV disease and in poor clinical condition. The reasons for this are comp...
Conference Material
|
Slide Presentation

Prevalence of asymptomatic Leishmania infection in people living with HIV (PLHIV) and progression to symptomatic visceral leishmaniasis in Bihar, India

Mahajan R, Owen SI, Kumar S, Kazmi S, Das P,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Journal Article
|
Research

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 m...
Journal Article
|
Research

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support...
Protocol
|
Research Protocol

Evaluation of qPCR on blood and skin microbiopsies, peripheral blood buffy coat smear, and urine antigen ELISA for diagnosis and test of cure for visceral leishmaniasis in HIV-coinfected patients in India: a prospective cohort study

Owen SI, Burza S, Kumar S, Verma N, Mahajan R,  et al.
2021-04-30 • BMJ Open
2021-04-30 • BMJ Open
INTRODUCTION
HIV coinfection presents a challenge for diagnosis of visceral leishmaniasis (VL). Invasive splenic or bone marrow aspiration with microscopic visualisation of Leishmani...
Journal Article
|
Research

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N,  et al.
2011-10-01 • Clinical Infectious Diseases
2011-10-01 • Clinical Infectious Diseases
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of lipo...
Journal Article
|
Research

Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Gonzalez Sanz M, Lima MA,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully u...